Anavex Life Sciences (NASDAQ:AVXL – Free Report) had its price target decreased by HC Wainwright from $54.00 to $40.00 in a research report released on Wednesday, Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Anavex Life Sciences’ Q1 2024 earnings at ($0.15) EPS, […]
By Chris Wack Anavex Life Sciences shares were down 30% to $6.50 after the company said its Anavex 2-73 study missed a primary endpoint. The clinical-stage.
Anavex Life Sciences Corp. (AVXL) shares went up by 11% on Tuesday following the announcement that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has approved their oral blarcamesine for Alzheimer's disease, making it eligible for submission of a Union Marketing Authorisation application in the EU.
By Sabela Ojea Shares of Anavex Life Sciences climbed on Tuesday after the company said it can submit a marketing authorization review application to the.